Johnson & Johnson (JNJ) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Johnson & Johnson (JNJ)

248.82

-4.22 (1.67%)

as of Jul 20, 2026, 8:00:00 pm Market Open.

697 watching

Investor Insights

Jul 20, 2026, 12:00 am

This summary was created by AI, based on 10 opinions in the last 12 months.

Johnson & Johnson (JNJ) has faced challenges in its cardio business, but experts are generally optimistic about its future, especially following a recent earnings report. The company is transitioning into a pharmaceutical pure-play after spinning off its orthopedics division, which has helped bolster its position in higher-margin sectors such as medical devices and pharmaceuticals. Many analysts believe that despite past legal issues related to talcum powder lawsuits, these concerns have diminished and are unlikely to significantly impact the stock's future performance. With a strong pipeline of drugs, particularly in oncology, JNJ's stock is seen as a promising investment, especially for dividend growth. Overall, the sentiment indicates that buyers may want to capitalize on potential weakness in the stock.

Consensus

Buy

Valuation

Fair Value

Similar

P&GA,PG

TOP PICK

Very high-quality stock.

BUY

A great blue-chip company. A wonderful line of consumer products, some good pharmaceuticals and, making money on their coated stent. This stock will not have fast growth.

TOP PICK

One of his 2 favourite areas is health care because of the demographics. You can buy at a discount to the market.

BUY

There is competition in the stent market. The whole health-care sector is a bit of a puzzle. Has been executing very well, but money just doesn't seem to want to flow into health-care.

TOP PICK

One of a handful of AAA Company's out there. Great dividend history. Reasonable P/E valuation. Hasn't participated in the strong market over the course of the last year or so.

TOP PICK

A non cyclical stock. Pays a dividend yield in the healthcare sector.

HOLD

They've been groeing their market share by 20% throughout the last 4 years. Trading at evaluation standards that are fantastic, looks attractive for long-term hold, Drug companies are undervalued., could see some good gains.

BUY

In the long term, it's a great diversified play in the healthcare sector.

DON'T BUY

Has been stuck around $50 mark. Took a big jump when they first produced a stent but they now have competition, which is taking quite a bit of market share. Could see it go a bit lower.

TOP PICK

A contrarian play. Has performed very well from a financial perspective. Growth prospect is a very positive. Very good long-term value.

BUY

Trading at a discounted valuation. They are getting competition with their stents. At a decent valuation. Should see some upside from here.

BUY

Pharmaceutical stocks are defensive in nature.In this environment, nobody's buying them.Will be dead money in the short term.A good price to buy out for the long-term.

BUY

They have a huge consumer business.The drug sector has been sluggish.Longer term this should pick up.

WEAK BUY

Book value is about $8 a share. Drug companies always seem to do well.

BUY

Stable growth. Valuation may be a little high, but OK.

Showing 586 to 600 of 628 entries

Most Recent Experts

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

David Driscoll

Liberty International Investment Management Inc

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Capital Area Planning Group

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Kevin Simpson

Capital Wealth Planning

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Johnson & Johnson (JNJ)